Global veterinary vaccines market analysis and insights
The global Veterinary Vaccines market estimated at US$8.47 billion in the year 2022 is now projected to grow at a CAGR of 6.18% and reach US$12.14 billion by 2028. This growth is primarily driven by the growing number of livestock and companion animals, rising prevalence of zoonotic diseases and increasing awareness about animal vaccination.
Veterinary vaccines encompass bio-prepared immunizations administered to both wild and domestic animals using either injectable or oral methods. These vaccines stimulate protective immune responses without causing illness. The purpose of veterinary vaccinations is to enhance immune function, minimize animal suffering, and mitigate the transmission of infectious zoonotic diseases. Their reliability, affordability, and capacity for prolonged preventive effects contribute to heightened livestock productivity on a global scale.
The growth of the veterinary vaccine market is driven by the rising demand for effective vaccination solutions and the prevalence of various infectious epizootic diseases. The global trend of domesticating companion and livestock animals, coupled with increased emphasis on pet well-being, as well as investments in innovative injectable manufacturing techniques within the pharmaceutical industry, all contribute to the market’s expansion.
Furthermore, the market growth is accelerated by advancements in vaccines incorporating DNA and RNA, resulting in improved efficacy, product stability, and administration methods. The development of intramuscular needle-free injections, along with heightened consumer awareness of their benefits such as enhanced safety and reduced discomfort, fuels growth. Additionally, the rising necessity for vaccinations to safeguard against disease-spreading microorganisms through animal-derived products like meat, leather, milk, eggs, and wool drives market progression. Moreover, a growing healthcare infrastructure and significant research and development endeavors aimed at enhancing immunization efficacy are expected to further propel the veterinary vaccine market over the forecast period.
Veterinary vaccines regional market insights
North American veterinary vaccines market is expected to grow significantly over the forecast period 2022-2028. This growth can be attributed to the owing to the increasing companion animal population and presence of major pharmaceutical companies in the region. United States contributed around 78% of the total North American veterinary vaccines market. It is estimated to have a market value of US$2.27 billion in the year 2022. Among the other noteworthy geographic markets are Canada and Mexico, each forecast to grow at 5.35% and 3.72% respectively over the 2022-2028 period.
Asia Pacific veterinary vaccines market is anticipated to witness an upsurge owing to the increase in livestock population and government initiatives in developing countries like China and India. Moreover, the market is being driven by high R&D expenditure by major players, combined with efforts to commercialize veterinary vaccines at affordable prices. China is expected to dominate the Asia-Pacific market and reach a market size of US$2.11 billion by 2028.
Within Europe, Germany, France, Italy and the U.K. are the key countries responsible for the significant growth of the regional market. Germany is expected to grow at a fastest CAGR of 5.39% over the forecast period.
Meanwhile, the under-developed countries in Middle East & Africa are expected to present lucrative opportunities for veterinary vaccine manufacturers to enter and expand their business.
Key players
Key players profiled in the report include Bayer de México SA de CV; Biogénesis Bagó SA; Boehringer Ingelheim International GmbH; Ceva Santé Animale; Dechra Pharmaceuticals Plc; Elanco Animal Health; Eli Lilly and Company; Heska Corporation; Hester Biosciences Ltd.; Indian Immunologicals Ltd.; Karyopharm Therapeutics, Inc.; Merck Animal Health; Morphogenesis, Inc.; Regeneus Ltd.; Virbac SA and Zoetis Inc., among others.
Competitive Landscape
Jan 23, 2023 – Merck Animal Health, a division of Merck & Co., Inc., announced the opening of a state-of-the-art manufacturing facility in Boxmeer, the Netherlands, for sterile filling and freeze drying of Companion Animal vaccines. Boxmeer is one of the company’s centers for the development and production of veterinary vaccines. The location is part of a manufacturing network in the Netherlands, including existing production and research facilities in Boxmeer and De Bilt that supports the company’s global leadership position in the animal health vaccine market.
Oct 10, 2022 – National Dairy Development Board subsidiary Indian Immunologicals Ltd (IIL) will be investing about ₹700 crore to set up a new animal vaccine manufacturing facility in Genome Valley, Hyderabad. The proposed facility will produce vaccines for FMD (Foot and Mouth disease) and other emerging diseases.
Veterinary vaccines market scope
- By type
- Livestock vaccines
- Companion animal vaccines
- Equine vaccines
- Aquaculture vaccines
- Others
- By technology
- Live attenuated vaccines
- Inactivated vaccines
- Recombinant vaccines
- Toxoid vaccines
- Subunit vaccines
- Others
- By disease
- Livestock disease
- Companion animals disease
- Equine disease
- Aquaculture
- Others
- By animal type
- livestock
- Cattle
- Pigs
- Sheep and goats
- Poultry
- Companion
- Dogs
- Cats
- Rabbits
- Others
- Equine/Horses
- Camels
- Others
- livestock
- By distribution channel
- Veterinary hospitals and clinics
- Animal health supply stores
- Online retailers
- Others
- By region
- North America
- South America
- Europe
- Asia Pacific
- Middle East and Africa
| Report Attribute | Details |
| No. of Pages | 246 |
| Published | August-2023 |
| Forecast Period | 2022-2028 |
| Estimated Market Size in 2022 | US$8.47 billion |
| Forecasted Market Size by 2028 | US$12.14 billion |
| CAGR | 6.18% |
| Regions Covered | North America, South America, Europe, Asia Pacific, Middle East and Africa |
| Companies Mentioned | Bayer de México SA de CV; Biogénesis Bagó SA; Boehringer Ingelheim International GmbH; Ceva Santé Animale; Dechra Pharmaceuticals Plc; Elanco Animal Health; Eli Lilly and Company; Heska Corporation; Hester Biosciences Ltd.; Indian Immunologicals Ltd.; Karyopharm Therapeutics, Inc.; Merck Animal Health; Morphogenesis, Inc.; Regeneus Ltd.; Virbac SA and Zoetis Inc., among others. |
The research report provides a comprehensive review of market trends (Technology, Product and Application analysis), market growth drivers, PEST Analysis (Political, Economic, Social and Technological Analysis) Market growth inhibitors, and strategic industry activities and SWOT Analysis of key players in the market. The report provides market estimates and forecast for geographic markets such as the North America (United States, Canada, Mexico and Rest of North America), South America (Brazil, Argentina Chile Colombia Peru Venezuela Ecuador and Rest of South America), Europe (Germany, France, U.K., Russia, Italy, Spain, Sweden, Netherlands, Poland, Austria, Belgium, Finland, Norway, Switzerland, Denmark, Czech Republic, Portugal and Rest of Europe), Asia-Pacific (China, Japan, South Korea, Taiwan, India, Australia, Indonesia, Philippines, Malaysia and Rest of Asia-Pacific), Middle East (Iran, Turkey, Kuwait, UAE, Israel, Oman, Bahrain, Saudi Arabia, Qatar, Egypt and Rest of Middle East) & Africa.
Research Methodology
